Hilary Hutton-Squire leads Global Value and Access at Gilead Sciences. She has 25 years’ experience in the Life Sciences Industry, leading teams in the US, UK, and Globally. Hilary has worked across a range of commercial functions at Gilead Sciences, Novartis and GSK. As Head of Global Value and Access, Hilary is responsible for ensuring that development strategies are designed with value demonstration in mind, and that evidence is generated to ensure that the maximum number of patients benefit from these innovations, whilst ensuring valuation that supports the innovation eco-system. Previously Hilary led Gilead’s HIV Treatment and Prevention business in the US. She has also worked as a Country General Manager, leading Gilead’s business across the UK and Ireland.

Hilary is passionate about improving Global Health; through innovation in medicines and by enabling services to get these medicines to the people who need them most.

Sandeep Duttagupta, PhD is currently the Vice President of Global Pricing & Market Access at Alnylam. In this role Sandeep’s responsibilities include overseeing Alnylam’s pricing and access strategies for its entire portfolio, managing the global governance around access, and working closely with Regional teams to maximize the value of our programs, and playing a key role in developing future innovative access programs per Alnylam’s Patient Access philosophy.

Sandeep brings over 25 years of global industry and management consulting experience, specializing in global pricing and market access for biopharmaceutical products. Most recently he was a Partner at DRG/Clarivate Consulting and Practice Lead for Global Pricing and Market Access. He joined erstwhile-DRG Consulting in 2018 and advised biopharmaceutical clients in their go-to-market pricing and patient access strategies across US, Europe, Japan, China, and Emerging Markets. He worked with both government and private healthcare payers across the globe to help key pharma and biotech clients maximize access to patients for innovative medicines.

Prior to DRG/Clarivate, Sandeep was at CBPartners, a NYC-based boutique life sciences strategy consulting firm specializing in value, access, and pricing, where he held the role of Senior Vice President, Business Development. During his tenure, he helped expand the firm’s business into a substantial number of new clients across various geographies. Prior to this, Sandeep spent 17 years at Pfizer, across positions of increasing responsibility, first within Global and US HEOR, and then for 10 years in various Global Pricing and Market Access functions. His last position was as the Vice President of P&MA for Pfizer’s Emerging Market Business Unit, where he had the opportunity to reshape internal thinking and business models in low-to-middle-income countries across Pfizer’s portfolio. Additionally, on behalf of PhRMA, he was often the face of the pharmaceutical industry in shaping industry-friendly government policies in a large number of countries.

Sandeep also serves as an Executive Board member for privately held Aquavit Pharmaceuticals and Celanese (NYSE: CE).

Sahil Kirpekar, MD, MPhil is currently the Chief Business Officer at atai Life Sciences, a company that was created with the vision of leveraging innovation in mental health, including psychedelics to bring novel treatments to patients in neuropsychiatry. In this role, Dr. Kirpekar is responsible for portfolio strategy and capital allocation, internal and external investments as well as early commercial capabilities for atai’s pipeline.

Immediately prior to joining atai, Dr. Kirpekar was at Otsuka Pharmaceutical Co., Ltd., for over eight years where he last served as the Global Head of Business and demonstrated his ability to build a successful pipeline of assets in CNS, Rare disease and Haem-Oncology. Dr. Kirpekar's diverse experience extends beyond his time at Otsuka. He has been the architect of several complex deals, and his leadership and strategic acumen led to the closing of significant transactions valued at over USD 2.7 billion, contributing to the on-going growth and success of the organization he has represented. He has built and managed multiple large teams and organizations, launched two drugs, has been responsible for early pipeline strategy and developed digital health tools.  He has also founded a company responsible for developing a drug delivery device addressing adherence issues, worked with the World Health Organization and had an academic position with the University of Cambridge.

Dr. Kirpekar's background as a trained physician makes him a compassionate and empathetic leader while giving him the necessary scientific depth as he tackles key strategic questions. He sees the bigger picture, and ultimately is driven by his commitment to patients in need.

Joep Muijrers joined Gilde in 2021 with two decades of broad experience in life sciences, including senior roles in portfolio management, company operations, and investment banking. Most recently, he served as Chief Financial Officer and Chief of Portfolio Strategy at PureTech Health (PRTC), a Boston-based biotech company focused on developing highly differentiated medicines for devastating diseases.

Prior to PureTech, Joep worked for ten years as a Portfolio Manager at LSP, where he invested in publicly-traded life sciences companies. Prior to joining LSP, Joep served as Director Corporate Finance and Capital Markets at Fortis Bank, where he focused on financing and M&A transactions for life sciences companies in Europe and the US.

Joep holds a PhD degree in Molecular Biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and a Master’s degree in Biochemistry from the University of Nijmegen.

Joep has served on the Board of Directors of seven healthcare companies and as an advisor to two not-for-profit entities. Joep is actively engaged in multi-stakeholder interaction and has been an invited speaker at events organized by the European Medicines Agency, DIA, NICE, ISPOR, BioCentury, BIO and other organizations.

At Gilde Healthcare he focuses on publicly traded companies that can deliver better care at lower cost.

Mel Walker is a senior advisor to life science companies with a passion for enabling access to innovation. He enjoys helping companies enhance their potential for global launch, partnering, or acquisition by integrating commercial and access perspectives at an early stage of R&D. Mel spent over two decades in the pharmaceutical industry in early and late phase commercial and access roles. He has held leadership positions at Roche, GSK, and Otsuka and launched multiple products across UK, European, and Global markets. Mel was a senior executive for ten years, sitting on global R&D, business development, digital health, and corporate strategy boards.